603087 甘李药业
已收盘 04-02 15:00:00
资讯
新帖
简况
甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证
智通财经 · 04-02 19:21
甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证
甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素
美股速递 · 03-31 21:39
甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素
甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%
美股速递 · 03-31 21:39
甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%
甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告
美股速递 · 03-31 21:39
甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告
甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点
美股速递 · 03-31 21:37
甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点
甘李药业最新公告：博凡格鲁肽新增适应症获临床试验批准
证券之星 · 03-24
甘李药业最新公告：博凡格鲁肽新增适应症获临床试验批准
3月23日甘李药业跌5.78%，招商国证生物医药指数(LOF)A基金重仓该股
证券之星 · 03-23
3月23日甘李药业跌5.78%，招商国证生物医药指数(LOF)A基金重仓该股
甘李药业最新公告：聘任王琦为财务负责人兼副总经理
证券之星 · 03-06
甘李药业最新公告：聘任王琦为财务负责人兼副总经理
甘李药业最新公告：拟使用不超过40亿元闲置自有资金进行现金管理
证券之星 · 03-06
甘李药业最新公告：拟使用不超过40亿元闲置自有资金进行现金管理
甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%
证券之星 · 03-02
甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%
甘李药业最新公告：获得GLR2037片药物临床试验批准通知书
证券之星 · 03-02
甘李药业最新公告：获得GLR2037片药物临床试验批准通知书
每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见
证券之星 · 03-01
每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见
甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见
证券之星 · 02-26
甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见
甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%
证券之星 · 02-24
甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%
甘李药业新提交“未公开”等2件商标注册申请
证券之星 · 02-15
甘李药业新提交“未公开”等2件商标注册申请
甘李药业新提交“未公开”等9件商标注册申请
证券之星 · 02-05
甘李药业新提交“未公开”等9件商标注册申请
每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%
证券之星 · 01-25
每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%
甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”
证券之星 · 01-24
甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”
甘李药业最新公告：2025年净利同比预增78.96%-95.23%
证券之星 · 01-21
甘李药业最新公告：2025年净利同比预增78.96%-95.23%
每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可
证券之星 · 01-18
每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":64.53,"timestamp":1775113200000,"preClose":65.38,"halted":0,"volume":7774978,"delay":0,"changeRate":-0.013,"floatShares":558000000,"shares":597000000,"eps":1.5499,"marketStatus":"已收盘","change":-0.85,"latestTime":"04-02 15:00:00","open":65,"high":65.31,"low":64.2,"amount":503000000,"amplitude":0.017,"askPrice":64.53,"askSize":100,"bidPrice":64.52,"bidSize":32,"shortable":0,"etf":0,"ttmEps":1.5499,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775179800000},"marketStatusCode":5,"adr":0,"adjPreClose":65.38,"symbolType":"stock","openAndCloseTimeList":[[1775093400000,1775100600000],[1775106000000,1775113200000]],"highLimit":71.92,"lowLimit":58.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.42,"roa":"--","peRate":41.634944,"roe":"7.21%","epsLYR":1.04,"committee":-0.249406,"marketValue":38544000000,"turnoverRate":0.0139,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-08。","floatMarketCap":35999000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2624058495","title":"甘李药业(603087.SH)子公司通过巴西国家卫生监督局GMP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2624058495","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624058495?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:21","pubTimestamp":1775128878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，近日，公司子公司甘李药业巴西贸易与医药进口有限责任公司(简称“甘李巴西”)收到巴西国家卫生监督局(简称“巴西ANVISA”)核准签发的药品生产质量管理规范(GMP)认证证书。认证范围：门冬胰岛素原料药、赖脯胰岛素原料药。本次顺利通过巴西ANVISA的GMP认证，为公司产品赖脯胰岛素和门冬胰岛素进入巴西市场奠定了坚实基础，对公司国际化战略推进具有积极意义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159100","BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143850390","title":"甘李药业GZR4注射液26周疗效显著：降糖效果优于来得时与德谷胰岛素","url":"https://stock-news.laohu8.com/highlight/detail?id=1143850390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143850390?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964378,"startTime":"0","endTime":"0","summary":"在第26周的治疗周期后，甘李药业研发的GZR4注射液展现出卓越的降糖能力，其降低糖化血红蛋白（HbA1c）的效果明显优于对照药物来得时（Lantus）和德谷胰岛素（Tresiba）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164271814","title":"甘李药业：一周一次Gzr4相比每日胰岛素，年注射次数减少超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164271814","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164271814?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964356,"startTime":"0","endTime":"0","summary":"甘李药业最新研发的Gzr4胰岛素产品，凭借其一周一次的给药方案，展现出显著优势。与传统的每日一次胰岛素相比，该药物可将患者每年的注射频率大幅降低超过85%。这一突破不仅极大提升了用药便利性，也为糖尿病患者提供了全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188766351","title":"甘李药业周制剂GZR4安全性表现优异，无严重低血糖事件报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1188766351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188766351?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:39","pubTimestamp":1774964352,"startTime":"0","endTime":"0","summary":"甘李药业研发的每周一次给药制剂GZR4在临床试验中展现出良好的安全性特征，研究期间未观察到严重低血糖事件的发生。该结果进一步验证了此类长效制剂在血糖控制方面的潜在优势，为糖尿病患者提供了更便捷、安全的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106815675","title":"甘李药业周制剂基础胰岛素GZR4注射液两项关键III期临床试验SUPER-1与SUPER-2均达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1106815675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106815675?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:37","pubTimestamp":1774964235,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其研发的每周一次基础胰岛素GZR4注射液，在两项关键性III期临床试验——SUPER-1与SUPER-2中，均成功达到了预设的主要研究终点。这一积极结果标志着该创新疗法在临床开发进程中取得了重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050489","title":"甘李药业最新公告：博凡格鲁肽新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050489","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050489?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:11","pubTimestamp":1774343466,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司全资子公司甘李药业山东有限公司近日收到国家药监局下发的《药物临床试验批准通知书》，同意其在研药品博凡格鲁肽(研发代号：GZR18)注射液新增适应症“成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停”开展临床试验。该药为每两周给药一次的GLP-1受体激动剂，目前正进行肥胖/超重体重管理及2型糖尿病适应症的Ⅲ期临床试验。截至2025年9月30日，该项目累计研发投入6.85亿元。国内目前仅礼来替尔泊肽获批该适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775192","title":"3月23日甘李药业跌5.78%，招商国证生物医药指数(LOF)A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621775192?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:25","pubTimestamp":1774254342,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日甘李药业跌5.78%创60日新低，收盘报56.2元，换手率1.78%，成交量9.91万手，成交额5.66亿元。重仓甘李药业的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数A。招商国证生物医药指数A目前规模为67.21亿元，最新净值0.3759，较上一交易日下跌1.6%，近一年下跌3.14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300024794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","161726","603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617934681","title":"甘李药业最新公告：聘任王琦为财务负责人兼副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2617934681","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617934681?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:30","pubTimestamp":1772793026,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司于2026年3月6日召开第五届董事会第七次会议，审议通过《关于聘任公司高级管理人员的议案》，同意聘任王琦为公司财务负责人兼副总经理，任期自本次董事会决议通过之日起至第五届董事会任期届满之日止。王琦具备担任公司高级管理人员的资格，符合相关法律法规中对上市公司高级管理人员的任职资格要求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600032622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617131681","title":"甘李药业最新公告：拟使用不超过40亿元闲置自有资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2617131681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617131681?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:29","pubTimestamp":1772792994,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司拟使用不超过40亿元人民币的闲置自有资金进行现金管理。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600032621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355649","title":"甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355649","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355649?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:38","pubTimestamp":1772462302,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，甘李药业报收于64.49元，较前一交易日下跌2.24%，最新总市值为385.2亿元。该股当日开盘65.0元，最高65.64元，最低63.83元，成交额达4.27亿元，换手率为1.19%。近日，甘李药业股份有限公司收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意公司自主研发的GLR2037片开展晚期前列腺癌的临床试验。公司已累计投入研发费用5,805.47万元。后续将按要求开展临床试验，待试验成功后申报生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616805503","title":"甘李药业最新公告：获得GLR2037片药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616805503","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616805503?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444462,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司近日收到国家药品监督管理局下发的关于在研药品GLR2037片的《药物临床试验批准通知书》，同意开展晚期前列腺癌的临床试验。前列腺癌是男性泌尿生殖道肿瘤中最常见的肿瘤之一，发病率在全球男性恶性肿瘤中排名第2位。截至2025年9月30日，该项目累计投入研发费用5805.47万元人民币。由于医药产品研发具有不确定性，公司将积极推进该项目并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616434558","title":"每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2616434558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616434558?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:11","pubTimestamp":1772302271,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，甘李药业报收于65.97元，较上周的64.99元上涨1.51%。本周，甘李药业2月26日盘中最高价报67.16元。本周关注点公司公告汇总：赖脯胰岛素和门冬胰岛素注射液获欧盟CHMP积极意见。）上市许可申请获得欧盟CHMP积极意见的公告甘李药业股份有限公司及其欧洲全资子公司甘李药业欧洲有限责任公司收到欧洲药品管理局通知，赖脯胰岛素注射液和门冬胰岛素注射液获得EMA人用药品委员会积极意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FSXEmain","603087","BK0239","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614101663","title":"甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2614101663","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614101663?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:13","pubTimestamp":1772097191,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司及其欧洲全资子公司甘李药业欧洲有限责任公司收到欧洲药品管理局通知，赖脯胰岛素注射液、门冬胰岛素注射液获得CHMP积极意见。CHMP建议欧盟委员会批准这两款药物作为生物类似药上市，用于治疗糖尿病。此次获得CHMP积极意见标志着公司产品在欧洲市场上市进程取得突破性进展，但能否获得欧盟委员会批准及获批时间仍存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600025772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FSXEmain","BK0239","603087","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613797510","title":"甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797510?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:34","pubTimestamp":1771929253,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，甘李药业报收于66.19元，较前一交易日上涨1.85%，最新总市值为395.36亿元。近日，甘李药业股份有限公司披露《关于变更保荐代表人的公告》。本次变更后，持续督导保荐代表人为赵陆胤女士和邵才捷女士，持续督导期至中国证监会和上交所规定结束为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611914188","title":"甘李药业新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2611914188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611914188?lang=zh_cn&edition=full","pubTime":"2026-02-15 06:09","pubTimestamp":1771106958,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日甘李药业股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来甘李药业股份有限公司新申请注册商标13件，截止目前公司共持有注册商标368件，另有66件商标尚在注册申请中。通过天眼查大数据分析，甘李药业股份有限公司共对外投资了7家企业，参与招投标项目2450次；财产线索方面有商标信息314条，专利信息119条，著作权信息4条；此外企业还拥有行政许可453个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609311829","title":"甘李药业新提交“未公开”等9件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2609311829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609311829?lang=zh_cn&edition=full","pubTime":"2026-02-05 06:29","pubTimestamp":1770244152,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日甘李药业股份有限公司新提交“未公开”等9件商标注册申请。商标申请详情如下：今年以来甘李药业股份有限公司新申请注册商标9件，截止目前公司共持有注册商标368件，另有62件商标尚在注册申请中。通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2447次；财产线索方面有商标信息300条，专利信息118条，著作权信息4条；此外企业还拥有行政许可453个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500003306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606823241","title":"每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606823241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606823241?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:57","pubTimestamp":1769281029,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，甘李药业报收于72.83元，较上周的71.82元上涨1.41%。本周关注点业绩披露要点：甘李药业预计2025年净利同比增长78.96%至95.23%。业绩披露要点甘李药业发布业绩预告，预计2025年全年归属净利润盈利11亿元至12亿元，同比增长78.96%至95.23%；扣非后净利润盈利7亿元至8亿元，同比增长62.63%至85.86%。控股股东甘忠如及其控制的旭特宏达合计持股占公司总股本39.80%，累计质押股份占其持股总数9.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605817372","title":"甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605817372","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605817372?lang=zh_cn&edition=full","pubTime":"2026-01-24 08:50","pubTimestamp":1769215839,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示甘李药业（603087）公布了一项国际专利申请，专利名为“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”，专利申请号为PCT/CN2025/102221，国际公布日为2026年1月15日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来甘李药业已公布的国际专利申请2个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.65亿元，同比减0.73%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012400011725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605012170","title":"甘李药业最新公告：2025年净利同比预增78.96%-95.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605012170","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605012170?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:50","pubTimestamp":1768989051,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)发布2025年度业绩预告，预计归属于上市公司股东的净利润为11.00亿元到12.00亿元，与上年同期相比增加78.96%到95.23%。报告期内，公司国内外收入增长，胰岛素制剂产品销量与销售额大幅上升，国际化战略推进取得成效，同时因转让甘甘江苏55%股权获得投资收益，带动净利润增长。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100030047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604892846","title":"每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2604892846","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604892846?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:42","pubTimestamp":1768671732,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，甘李药业报收于71.82元，较上周的71.0元上涨1.15%。本周关注点公司公告汇总：甘精胰岛素注射液获得欧盟委员会上市许可，适应症为治疗成人、青少年和2岁及以上儿童糖尿病。甘李药业股份有限公司近日收到埃塞俄比亚国家食品药品监督管理局核准签发的甘精胰岛素注射液及预填充注射笔注册批件，批件号分别为11865/13208/NMR/2025和11864/13210/NMR/2025。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","FESXmain","FSXEmain","603087"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775149646099,"stockEarnings":[{"period":"1week","weight":0.1014},{"period":"1month","weight":0.0302},{"period":"3month","weight":-0.052},{"period":"6month","weight":-0.1498},{"period":"1year","weight":0.4147},{"period":"ytd","weight":-0.052}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.0125},{"period":"6month","weight":0.0094},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"94714人(较上一季度增加22.53%)","perCapita":"5889股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}